PUBLISHER: Polaris Market Research | PRODUCT CODE: 1150079
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1150079
The global Migraine Drugs market size is expected to reach USD 8.79 billion by 2030, according to a new study by Polaris Market Research. The report "Migraine Drugs Market Share, Size, Trends, Industry Analysis Report, By Product Type (Acute/Abortive Treatment, Preventive/Prophylactic Treatment); By Therapeutic Class; By Route of Administration; By End-Use; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The increasing prevalence of neurological illnesses such as migraine among the teenage population as a result of a more sedentary lifestyle is expected to boost the market growth in the future years.
For instance, according to the National Institute of Health, Migraine affects about one billion people worldwide each year and is one of the most frequent neurologic illnesses, with a higher incidence and morbidity, especially among young people and females. From 1990 to 2019, the worldwide age-standardized frequency of migraine grew by 1.7%, with 1.1 billion prevalent instances in 2019.
Moreover, the increasing launch of Calcitonin gene-related peptide (CGRP)-based medicines and significant unmet requirements are some of the important reasons driving market expansion. For instance, in December 2019, Ubrelvy (ubrogepant) tablets were approved by the Food and Drug Administration for the acute (immediate) therapy of migraine, either with or without vision in adults.
Ubrelvy is not approved for the prevention of migraines. It is the first medicine licensed for the acute treatment of migraines in the category of oral calcitonin gene-related peptides (CGRP) antagonists. Thus, this rising prevalence, along with the increasing approvals, is driving market growth over the forecast period.
Furthermore, an increase in females number and a rise in patient awareness about migraine prevention and treatment are major drivers driving the market growth. Migraine headaches are more common in women than in men. According to the National Institute of Health of Migraine Association of Ireland, the global population in 2018 had a female migraineur to male migraineur ratio of 3:1. This is due to variations in estrogen levels in females, particularly during menstruation.
Furthermore, hormonal drugs, including oral contraceptives and hormone replacement treatment, may aggravate migraine in women. As a result, an increase in the worldwide female population is expected to drive the market growth of the migraine drugs.
Migraine Drugs Market Report Highlights
Online pharmacy segment is expected to grow at a significant CAGR over the forecast period. It is the quickest segment, offering migraine drugs through e-commerce platforms. The majority of the drugs given by online pharmacy chains are for the treatment of severe migraines.
Preventive/ Prophylactic Treatment segment accounted for a lucrative revenue share. Migraine prevention methods lessen migraine frequency and severity. Beta-blockers, botulism toxin toxins, and topiramate are the main pharmacological types used in preventive therapy.
Asia Pacific is expected to grow at a significant CAGR over the projected period. The Asia Pacific region is expected to grow significantly in the future, due to increased demand for improved health centers and improvements in the healthcare system.
The global players include Allergan, Alder Biopharmaceuticals, AstraZeneca, Amgen Inc., eNeura Inc., Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, and Teva Pharmaceutical.
Polaris Market Research has segmented the migraine drugs market report based on product type, therapeutic class, end-use, route of administration, and region:
Migraine Drugs, Product Type Outlook (Revenue - USD Billion, 2018 - 2030)
Acute / Abortive Treatment
Preventive/ Prophylactic Treatment
Migraine Drugs, Therapeutic Class Outlook (Revenue - USD Billion, 2018 - 2030)
Triptans
Acetylcholine Inhibitors/ neurotoxins
Ergot Alkaloids
NSAIDs
Ditans
CGRP small molecule antagonists
CGRP monoclonal antibodies
Others
Migraine Drugs, Route of Administration Outlook (Revenue - USD Billion, 2018 - 2030)
Oral
Injectables
Others
Migraine Drugs, End-Use Outlook (Revenue - USD Billion, 2018 - 2030)
Hospital pharmacies
Retail pharmacies
Online pharmacies
Migraine Drugs, Regional Outlook (Revenue - USD Billion, 2018 - 2030)
North America
U.S
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Latin America
Argentina
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Figure 1. Global Migraine Drugs Market, 2018 - 2030 (USD Billion)
Figure 2. Integrated Ecosystem
Figure 3. Research Methodology: Top-Down & Bottom-Up End-Use
Figure 4. Market by Geography
Figure 5. Porter's Five Forces
Figure 6. Market by Product Type
Figure 7. Global Migraine Drugs Market, by Product Type, 2021 & 2030 (USD Billion)
Figure 8. Market by End-Use
Figure 9. Global Migraine Drugs Market, by End-Use, 2021 & 2030 (USD Billion)
Figure 10. Market by Therapeutic Class
Figure 11. Global Migraine Drugs Market, by Therapeutic Class, 2021 & 2030 (USD Billion)
Figure 12. Market by Route of Administration
Figure 13. Global Migraine Drugs Market, by Route of Administration, 2021 & 2030 (USD Billion)
Figure 14. Migraine Drugs Market Assessment, By Geography, 2018 - 2030 (USD Billion)
Figure 15. Strategic Analysis - Migraine Drugs Market